IL148672A0 - Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines - Google Patents

Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines

Info

Publication number
IL148672A0
IL148672A0 IL14867200A IL14867200A IL148672A0 IL 148672 A0 IL148672 A0 IL 148672A0 IL 14867200 A IL14867200 A IL 14867200A IL 14867200 A IL14867200 A IL 14867200A IL 148672 A0 IL148672 A0 IL 148672A0
Authority
IL
Israel
Prior art keywords
octoxynol
vaccines
adjuvant
combination
sorbitan ester
Prior art date
Application number
IL14867200A
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9922703.5A external-priority patent/GB9922703D0/en
Priority claimed from GB0016685A external-priority patent/GB0016685D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of IL148672A0 publication Critical patent/IL148672A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IL14867200A 1999-09-24 2000-09-22 Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines IL148672A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9922703.5A GB9922703D0 (en) 1999-09-24 1999-09-24 Vaccine
GB0016685A GB0016685D0 (en) 2000-07-06 2000-07-06 Novel compounds
PCT/EP2000/009366 WO2001021207A2 (en) 1999-09-24 2000-09-22 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines

Publications (1)

Publication Number Publication Date
IL148672A0 true IL148672A0 (en) 2002-09-12

Family

ID=26244613

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14867200A IL148672A0 (en) 1999-09-24 2000-09-22 Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines

Country Status (17)

Country Link
EP (1) EP1221971A2 (en)
JP (1) JP2003509473A (en)
KR (1) KR20020038770A (en)
CN (1) CN1391483A (en)
AU (1) AU765824B2 (en)
BR (1) BR0014282A (en)
CA (1) CA2383413A1 (en)
CO (1) CO5200837A1 (en)
CZ (1) CZ20021043A3 (en)
HK (1) HK1049106A1 (en)
HU (1) HUP0202885A3 (en)
IL (1) IL148672A0 (en)
MX (1) MXPA02003067A (en)
NO (1) NO20021433L (en)
PL (1) PL355163A1 (en)
TR (1) TR200200774T2 (en)
WO (1) WO2001021207A2 (en)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0909323B1 (en) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Helicobacter pylori bacterioferritin
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
AU2002227365A1 (en) 2000-12-07 2002-06-18 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
CA2476626A1 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
SI2351579T1 (en) 2002-10-11 2017-05-31 Glaxosmithkline Biologicals Sa Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
CN101926988B (en) 2003-01-30 2014-06-04 诺华疫苗和诊断有限公司 Injectable vaccines against multiple meningococcal serogroups
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
CA2522379C (en) 2003-04-10 2012-10-23 Chiron Corporation The severe acute respiratory syndrome coronavirus
US9107831B2 (en) 2003-06-02 2015-08-18 Novartis Vaccines And Diagonstics, Inc. Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
ATE506963T1 (en) 2003-10-02 2011-05-15 Novartis Vaccines & Diagnostic COMBINATION VACCINES AGAINST MENINGITIS
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
WO2005107797A1 (en) 2004-03-09 2005-11-17 Chiron Corporation Influenza virus vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
PL1740217T3 (en) 2004-04-30 2012-03-30 Novartis Ag Meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
CA2567446C (en) 2004-05-21 2018-01-02 Chiron Corporation Alphavirus vectors for respiratory pathogen vaccines
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
PT2682126T (en) 2005-01-27 2017-02-28 Children`S Hospital & Res Center At Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
HUE030881T2 (en) 2005-02-18 2017-06-28 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
WO2007015441A1 (en) 2005-08-01 2007-02-08 Hisamitsu Pharmaceutical Co., Inc. Adjuvant or pharmaceutical preparation for transdermal or transmucosal administration
JP2009511636A (en) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Mucosal and systemic immunity with alphavirus replicon particles
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP2009514838A (en) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Adjuvant vaccine containing non-virion antigen prepared from influenza virus grown in cell culture
WO2007052057A2 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adminstration routes for priming/boosting with influenza vaccines
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
DK2478916T3 (en) 2006-01-27 2020-06-15 Seqirus Uk Ltd Influenza vaccines containing hemagglutinin and matrix proteins
US8535683B2 (en) 2006-03-22 2013-09-17 Abbott Biologicals B.V. Intranasal or inhalational administration of virosomes
ES2376492T3 (en) 2006-03-23 2012-03-14 Novartis Ag IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS.
CA2646349A1 (en) * 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
WO2007126825A2 (en) 2006-03-31 2007-11-08 Novartis Ag Combined mucosal and parenteral immunization against hiv
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
AU2007285484B2 (en) 2006-08-16 2013-05-02 Novartis Ag Immunogens from uropathogenic Escherichia coli
ES2694805T7 (en) 2006-09-11 2021-10-21 Seqirus Uk Ltd Manufacture of flu virus vaccines without using eggs
SG177141A1 (en) 2006-12-06 2012-01-30 Novartis Ag Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP2123296B1 (en) * 2007-01-31 2019-05-22 Hisamitsu Pharmaceutical Co., Inc. Adjuvant for transdermal or transmucosal administration and pharmaceutical preparation containing the same
EP2185191B1 (en) 2007-06-27 2012-09-12 Novartis AG Low-additive influenza vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8815253B2 (en) 2007-12-07 2014-08-26 Novartis Ag Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
NZ601543A (en) 2007-12-21 2013-03-28 Novartis Ag Mutant forms of streptolysin o
EP2886551A3 (en) 2008-02-21 2015-09-23 Novartis AG Meningococcal fhbp polypeptides
US9511131B2 (en) 2008-03-10 2016-12-06 Children's Hospital & Research Center Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
NZ592977A (en) 2008-12-09 2013-01-25 Pfizer Vaccines Llc IgE CH3 PEPTIDE VACCINE
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
NZ594029A (en) 2009-01-12 2014-01-31 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
JP5642712B2 (en) 2009-02-10 2014-12-17 ノバルティス アーゲー Influenza vaccine with low amounts of squalene
RU2011140508A (en) 2009-03-06 2013-04-20 Новартис Аг Chlamydia antigens
CN109248313B (en) 2009-04-14 2023-01-17 葛兰素史密丝克莱恩生物有限公司 Compositions for immunization against staphylococcus aureus
KR101450958B1 (en) 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 Pneumococcal vaccine and uses therof
EP2442826B1 (en) 2009-06-15 2015-07-08 National University of Singapore Influenza vaccine, composition, and methods of use
JP2012532600A (en) 2009-07-07 2012-12-20 ノバルティス アーゲー Conserved E. coli immunogen
ES2918381T3 (en) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa RSV F protein compositions and methods for producing the same
PT2464658E (en) 2009-07-16 2015-01-14 Novartis Ag Detoxified escherichia coli immunogens
NZ618391A (en) 2009-07-30 2015-07-31 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
KR101660578B1 (en) 2009-09-03 2016-09-27 화이자 백신스 엘엘씨 Pcsk9 vaccine
CA2779798C (en) 2009-09-30 2019-03-19 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
BR112012010531A2 (en) 2009-10-27 2019-09-24 Novartis Ag "fhbp meningococcal modification polypeptides"
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011077309A2 (en) 2009-12-22 2011-06-30 Pfizer Vaccines Llc Vaccine compositions
EP2519265B1 (en) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Polysaccharide immunogens conjugated to e. coli carrier proteins
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
EP2552942B1 (en) 2010-03-30 2017-12-27 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
CA2796314A1 (en) 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US20130171185A1 (en) 2010-07-06 2013-07-04 Ethan Settembre Norovirus derived immunogenic compositions and methods
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
PT2667892T (en) 2011-01-26 2019-06-07 Glaxosmithkline Biologicals Sa Rsv immunization regimen
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
PT2707385T (en) 2011-05-13 2017-12-19 Glaxosmithkline Biologicals Sa Pre-fusion rsv f antigens
JP2014520807A (en) 2011-07-06 2014-08-25 ノバルティス アーゲー Immunogenic compositions and uses thereof
EP2729165B1 (en) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US10030052B2 (en) 2011-07-25 2018-07-24 Glaxosmithkline Biologicals Sa Parvovirus Vp1 unique region polypeptides and compositions thereof
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP3563865A3 (en) 2012-05-04 2019-12-04 Pfizer Inc Prostate-associated antigens and vaccine-based immunotherapy regimens
SG11201407440WA (en) 2012-05-22 2014-12-30 Novartis Ag Meningococcus serogroup x conjugate
WO2014005958A1 (en) 2012-07-06 2014-01-09 Novartis Ag Immunogenic compositions and uses thereof
EA201590427A1 (en) 2012-10-02 2015-09-30 Глаксосмитклайн Байолоджикалс С.А. NONLINEAR SUCHARIDE CONJUGATES
RU2015106791A (en) 2012-10-03 2016-11-20 Глэксосмитиклайн Байолоджикалз Са IMMUNOGENIC COMPOSITIONS
AU2013351182C1 (en) 2012-11-30 2018-11-08 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
CA2909586C (en) 2013-05-15 2021-08-31 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
WO2015064710A1 (en) 2013-10-31 2015-05-07 久光製薬株式会社 Adjuvant composition, adjuvant preparation containing same, and kit
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2015208821B2 (en) 2014-01-21 2017-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
CA3212723A1 (en) 2014-07-23 2016-01-28 Peter T. Beernink Factor h binding protein variants and methods of use thereof
FI3244917T3 (en) 2015-01-15 2023-05-25 Pfizer Immunogenic compositions for use in pneumococcal vaccines
US10576131B2 (en) 2015-06-03 2020-03-03 Affiris Ag IL-23-p19 vaccines
WO2017005851A1 (en) 2015-07-07 2017-01-12 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
TWI756893B (en) 2015-07-21 2022-03-01 美商輝瑞股份有限公司 Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CA2954892A1 (en) 2016-01-19 2017-07-19 Pfizer Inc. Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens
DK3570879T3 (en) 2017-01-20 2022-04-11 Pfizer Immunogenic compositions for use in pneumococcal vaccines
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2022512345A (en) 2018-12-12 2022-02-03 ファイザー・インク Immunogenic Multiple Heteroantigen Polysaccharide-Protein Conjugates and Their Use
JP7239509B6 (en) 2019-02-22 2023-03-28 ファイザー・インク Method for purifying bacterial polysaccharides
JP2022528158A (en) 2019-04-10 2022-06-08 ファイザー・インク Immunogenic composition containing conjugated capsule sugar antigen, kit containing it and its use
IL292494A (en) 2019-11-01 2022-06-01 Pfizer Escherichia coli compositions and methods thereof
AU2021224078B2 (en) 2020-02-21 2024-01-18 Pfizer Inc. Purification of saccharides
EP4107170A2 (en) 2020-02-23 2022-12-28 Pfizer Inc. Escherichia coli compositions and methods thereof
TW202227467A (en) 2020-10-27 2022-07-16 美商輝瑞大藥廠 Escherichia coli compositions and methods thereof
KR20230097160A (en) 2020-11-04 2023-06-30 화이자 인코포레이티드 Immunogenic compositions for use in pneumococcal vaccines
JP2023549736A (en) 2020-11-10 2023-11-29 ファイザー・インク Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TWI750929B (en) * 2020-12-02 2021-12-21 林建宏 Temperature-sensitive adjuvant for aerosol immunity and its preparation method
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
MX2023009728A (en) 2021-02-19 2023-08-30 Sanofi Pasteur Inc Meningococcal b recombinant vaccine.
WO2022234483A1 (en) 2021-05-04 2022-11-10 King Abdullah University Of Science And Technology Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
TW202306969A (en) 2021-05-28 2023-02-16 美商輝瑞大藥廠 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20240090A1 (en) 2021-05-28 2024-01-16 Pfizer IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND THEIR USES
WO2023079528A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
WO2023079529A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Re-focusing protein booster immunization compositions and methods of use thereof
CA3237496A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024018061A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Use of bordetella strains for the treatment of chronic obstructive pulmonary disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
NL8403195A (en) * 1984-10-19 1986-05-16 Nederlanden Staat IMMUNOGENIC COMPLEXES AND VACCINES CONTAINING THESE.
CA1291036C (en) * 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals

Also Published As

Publication number Publication date
CZ20021043A3 (en) 2002-08-14
TR200200774T2 (en) 2002-08-21
HK1049106A1 (en) 2003-05-02
CA2383413A1 (en) 2001-03-29
CO5200837A1 (en) 2002-09-27
WO2001021207A2 (en) 2001-03-29
AU7907000A (en) 2001-04-24
NO20021433D0 (en) 2002-03-21
AU765824B2 (en) 2003-10-02
JP2003509473A (en) 2003-03-11
WO2001021207A3 (en) 2001-09-27
HUP0202885A2 (en) 2002-12-28
NO20021433L (en) 2002-05-21
BR0014282A (en) 2002-05-21
PL355163A1 (en) 2004-04-05
HUP0202885A3 (en) 2004-07-28
CN1391483A (en) 2003-01-15
MXPA02003067A (en) 2002-09-30
KR20020038770A (en) 2002-05-23
EP1221971A2 (en) 2002-07-17

Similar Documents

Publication Publication Date Title
IL148672A0 (en) Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
AU2003235707A8 (en) Immunogenic preparations and vaccines on the basis of mrna
HUP0200898A3 (en) Derivatives of venlafaxine and methods of preparing and using the same
AU6118001A (en) Combination therapeutic compositions and methods of use
AU6124401A (en) Infrared thermography and methods of use
EP1227821A4 (en) Therapeutic compositions and methods of use thereof
IL162328A0 (en) Adjustable chair and method of use
EP1254195A4 (en) Deicing compositions and methods of use
IL148247A (en) Vaccine composition and uses thereof
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2001241918A1 (en) Methods of enhancing activity of vaccines and vaccine compositions
MXPA02000779A (en) Highly purified cytokine activating factor and methods of use.
EP1326625A4 (en) Immunogenic composition of hepatitis c and methods of use thereof
AU2002363938A8 (en) Methods and use of motoneuronotropic factors
EP1086215A4 (en) Preparation and use of superior vaccines
EP1161451A4 (en) Human endokine alpha and methods of use
EP1263935A4 (en) Scytonemin and methods of using thereof
AU2001233588A1 (en) New toralactone and its derivation and the use of decreasing blood-fat and losing weight
AU2001257393A1 (en) Enhanced anti-corrosive protective coverings and methods of use
PL357906A1 (en) Combination of carboxyalkylethers with antihypertensives and pharmaceutical use
GB0007217D0 (en) Materials and methods relating to the treatment of leukaemias
AU2001269106A1 (en) Novel alpha expressed in heart and testis
AU2001261785A1 (en) Vdup1 promoter and methods of use thereof
AUPQ692200A0 (en) Vaccines and methods for the treatment of human melanoma
AUPP974099A0 (en) Vaccines and methods for the treatment of human melanoma